These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 22005545)
21. Summary of presentations from the 46th annual meeting of the American Society Of Clinical Oncology (2010): focus on developmental therapeutics related to lung cancer. Morgensztern D; Pennell NA; Subramanian J; Govindan R Clin Lung Cancer; 2011 Mar; 12(2):94-9. PubMed ID: 21550555 [TBL] [Abstract][Full Text] [Related]
22. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology]. Ludwig WD Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103 [TBL] [Abstract][Full Text] [Related]
31. Doubling down with inhibitors of Notch and Hedgehog signaling pathways. Weiss GJ J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S409-10. PubMed ID: 23160337 [No Abstract] [Full Text] [Related]
32. The Future of Molecular Medicine: Biomarkers, BATTLEs, and Big Data. Kim ES Am Soc Clin Oncol Educ Book; 2015; ():22-7. PubMed ID: 25993137 [No Abstract] [Full Text] [Related]
33. Special issue: Current vision on target enzymes for cancer therapy. Bishayee A; Kamal MA Semin Cancer Biol; 2019 Jun; 56():iii-v. PubMed ID: 30503852 [No Abstract] [Full Text] [Related]
35. The clinical development of molecularly targeted agents in combination with radiation therapy: a pharmaceutical perspective. Ataman OU; Sambrook SJ; Wilks C; Lloyd A; Taylor AE; Wedge SR Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e447-54. PubMed ID: 22819210 [TBL] [Abstract][Full Text] [Related]
36. Personalized lung cancer treatment based on molecular determinants. Simon GR J S C Med Assoc; 2011 Oct; 107(5):183-4. PubMed ID: 22057801 [No Abstract] [Full Text] [Related]
37. Personalized-medicine trials on the rise. Benowitz S J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496 [No Abstract] [Full Text] [Related]
38. Advances highlighted at US cancer meeting. McCarthy M Lancet; 2002 May; 359(9320):1835. PubMed ID: 12044383 [No Abstract] [Full Text] [Related]
39. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers. Singh N; Krishnakumar S; Kanwar RK; Cheung CH; Kanwar JR Drug Discov Today; 2015 May; 20(5):578-87. PubMed ID: 25433305 [TBL] [Abstract][Full Text] [Related]
40. [Chemoradiotherapy Using Molecular Targeted Therapy]. Akamatsu H Gan To Kagaku Ryoho; 2018 Mar; 45(3):416-418. PubMed ID: 29650895 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]